PBD Dimer Conjugates with Labile Linker for Targeted Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in achieving maximal efficacy with minimal toxicity due to non-selective delivery of cytotoxic agents, leading to unacceptable toxicity levels in normal cells, and existing benzodiazepine derivatives that can crosslink DNA have limited therapeutic indices.
Innovation Solution
Development of PBD and IBD dimer conjugates with a labile linker connected to a cell binding agent, where only one monomer unit is linked through the N10 position, allowing for the formation of an imine bond after release, maintaining an amine bond in the other monomer, thereby avoiding DNA crosslinking and enhancing therapeutic index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzodiazepine derivatives that can crosslink DNA are used, then cytotoxic efficacy is improved, but therapeutic index is limited due to toxicity in normal cells
Solution Approach 1:
The benzodiazepine dimer is divided into two monomer units with different functionalities: one monomer contains an imine bond capable of DNA crosslinking, while the other contains an amine bond that prevents crosslinking. This segmentation allows the molecule to deliver cytotoxic effects through the imine-containing monomer while the amine-containing monomer reduces off-target DNA crosslinking and toxicity to normal cells.
Solution Approach 2:
Different parts of the dimer molecule have different chemical properties: the imine-bearing monomer provides localized cytotoxic activity at the target site, while the amine-bearing monomer provides localized protection against non-specific DNA crosslinking. This local quality differentiation resolves the contradiction between efficacy and toxicity.
2Adaptability or versatility
If antibody-drug conjugates are used for targeted delivery, then selectivity is improved, but toxicity to normal cells remains unacceptable
Solution Approach 1:
The conjugate system segments the cytotoxic function (imine monomer) from the protective function (amine monomer), allowing targeted delivery via antibody to bring the imine monomer to tumor cells while the amine monomer remains to prevent systemic DNA crosslinking and reduce toxicity to normal cells during circulation and off-target exposure.
Solution Approach 2:
The amine-containing monomer acts as an intermediary protective element that prevents direct interaction between the cytotoxic imine monomer and normal cell DNA, thereby mediating reduced toxicity while maintaining the cytotoxic efficacy of the imine monomer against target tumor cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel conjugates demonstrate a higher therapeutic index with improved selectivity and reduced toxicity by releasing active PBD/IBD compounds that do not retain linker components, ensuring effective cytotoxicity while minimizing harm to non-target cells.
Implementation Method 1
only one monomer unit is linked through the N10 position, allowing for the formation of an imine bond after release, maintaining an amine bond in the other monomer
Data Source
AI summary
Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.